Navigation Links
Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
Date:9/14/2007

r does matter -- especially when it comes to lung cancer," said James A. Bianco, M.D., president and CEO of CTI. "This should be a national wake up call for increased awareness and research into lung cancer and gender-based medicine. Women are affected by lung cancer differently than men, and they respond differently to treatment. Through our XYOTAX studies, we continue to explore ways to turn a negative -- high levels of estrogen -- into a positive in our continuing efforts to make cancer more treatable."

About XYOTAX(TM)

XYOTAX(TM) (paclitaxel poliglumex) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that XYOTAX is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that XYOTAX metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies. XYOTAX is being studied in non-small cell lung and ovarian cancers as well as in several investigator-sponsored trials for prostate and breast cancers.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products a
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
5. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
6. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
7. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
8. Study Supports Cost-Effectiveness of Medtronics Spasticity Treatment for Children with Cerebral Palsy
9. Analyzers Offer Point-of-Care Lipid Panels
10. 2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
11. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... SHANGHAI, March 5, 2015 WuXi PharmaTech (Cayman) ... R&D capability and technology platform company serving the pharmaceutical, ... and the United States, today announced its financial results ... Fourth-Quarter 2014 Highlights , Net Revenues ... , Laboratory Services Net Revenues Grew 17.7% Year Over ...
(Date:3/5/2015)... Germany , March 5, 2015 ... and CureVac today announced that the foundation has ... million) in CureVac, a leading clinical-stage biopharmaceutical company ... the agreement, the foundation will also provide separate ... based on CureVac,s proprietary messenger RNA (mRNA) platform. ...
(Date:3/5/2015)... , March 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... second quarter ended January 31, 2015 on Thursday, March 12 ... discuss the results at 11:00 AM ET. ... 5 to 10 minutes before the beginning of the call. ... the call will be available from Thursday, March 12, 2015 ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
(Date:3/6/2015)... 06, 2015 At Natural Products ... today the launch of its powerful, location-aware iOS ... and sustainable products at any retailer that carries ... at Expo West Booth 6054. , Makeena’s ... Kosher, non-GMO, organic, Paleo, and vegan, among many ...
(Date:3/6/2015)... Since Medicare began paying for chronic care ... an overwhelming demand from providers for straightforward guidance on ... The Centers for Medicare & Medicaid Services (CMS) ... updated white paper—“ Providing and Billing Medicare for Chronic ... yet practical “how to” manual for providers looking to ...
(Date:3/6/2015)... 06, 2015 Jvion, the Atlanta-based ... of a Clostridium Difficile (C Diff) predictive use ... Diff use case is the latest in a ... acquired infections, chronic conditions, and individual illnesses. Using ... Diff solution flags at risk individuals to help ...
(Date:3/6/2015)... Utilizing the latest in nutritional science to help ... has enabled Diet Doc to add powerful new ... of fat loss enhancement medications. And now, they are ... to help people throughout the country begin losing dangerous ... appealing to new clients because they can receive Appetite ...
(Date:3/6/2015)... March 06, 2015 The Gluten-Free ... Celiac Association, is pleased to announce that Dufflet ... Rosenberg, has expanded their product line of gluten-free ... as scrumptious and as satisfying as any of ... scratch, and never contains hydrogenated fats or oils, ...
Breaking Medicine News(10 mins):Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Updated PYA White Paper Meets Demand for Guidance on Providing and Billing Medicare for Chronic Care Management 2Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 3Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 4Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4
... RESEDA, Calif., June 16 The famed nonprofit Los ... prevention and,fitness program designed to address one of the ... by the Jewish Community Foundation,the largest manager of charitable ... new fall prevention and fitness program becomes part of ...
... RELEASE, 16 June 2008] A unique new study from the ... of families and the public have little impact on if ... or the opposite sex. Instead, hereditary factors and the individual,s ... sexual partners. , The study is the largest in the ...
... recognize partners, innovative use of Microsoft technology to ... customer expectations and solve business ... partners,that delivered exemplary solutions to customers, Microsoft Corp. ... Microsoft Partner of the,Year Awards. The awards honor ...
... 16 BME (BioMedical Enterprises,Inc.), a privately held ... implant technology, today announced the launch of the ... fixation of,bone., The BOSS is an orthopaedic ... adhesion. Like the BME OSStaple(TM) product line, the ...
... Comprehensive Cancer Center, has been appointed by President Bush to the ... appointees named to the board on June 12, 2008. , The ... National Cancer Institute (NCI). The role of the board is ... Services and the director of the NCI on issues that ...
... provider based at The University of Queensland, and Q-Pharm, ... have formed a strategic alliance. , The alliance ... clients in the biotechnology and pharmaceutical industries. , ... the two businesses, which are both commercialisation enterprises of ...
Cached Medicine News:Health News:Los Angeles Jewish Home Institutes New Fall Prevention Program With Jewish Community Foundation Grant 2Health News:Los Angeles Jewish Home Institutes New Fall Prevention Program With Jewish Community Foundation Grant 3Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 2Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 3Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 4Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 5Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 6Health News:Microsoft Announces 2008 Partner of the Year Awards Finalists and Winners 7Health News:BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the Barbed OSStaple(TM) (BOSS) Nitinol Implant 2Health News:TetraQ and Q-Pharm form strategic alliance 2Health News:TetraQ and Q-Pharm form strategic alliance 3
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
... The Identity pacemaker family, which ... pacemaker, provides clinicians with the ... including the revolutionary AF Suppression™ ... U.S. commercially approved algorithm designed ...
Innovative new tools for more efficient patient management begin when the pacemaker is implanted. These sophisticated tools are in effect each day, and they help automate follow-up tasks....
The INSIGNIA® pacing systems allow the physician to provide customized adaptive-rate pacing therapy to meet individual patient needs....
Medicine Products: